HPV vaccines: State of the art

Journal of Cellular Physiology

Volumn 224, Issue 3, 2010, Pages 601-604

  D'Andrilli, Giuseppina ^a   Bovicelli, Alessandro ^a,b   Giordano, Antonio ^a,c  

^a Temple University   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; PAPILLOMATOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VULVA CANCER;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 77954614806     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22174     Document Type: Review

References (16)

1. Arbyn M, Dillner J. 2007. Review of current knowledge on HPV vaccination: An appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 38:189-197.
2. Beller U, Abu-Rustum NR. 2009. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol 113:550-552.
3. Bermudez-Humaran LG, Langella P. 2010. Perspectives for the development of human papillomavirus vaccines and immunotherapy. Expert Rev Vaccines 9:35-44.
4. Cuzick J. 2010. WITHDRAWN: Long-term cervical cancer prevention strategies across the globe. Gynecol Oncol. PMID:20129652 [Epub ahead of print].
5. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. 2009. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin 5:332-340.
6. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, 2009. Comparison of the immunogenicity and safety of Cervarix() and Gardasil((R)) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5:705-719.
7. Hakim AA, Dinh TA. 2009. Worldwide impact of the human papillomavirus vaccine. Curr Treat Options Oncol 10:44-53.
8. Harper DM. 2009a. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 8:1663-1679.
9. Harper DM. 2009b. Prevention of human papillomavirus infections and associated diseases by vaccination: A new hope for global public health. Public Health Genomics 12:319-330.
10. Majewski S, Bosch FX, Dillner J, Iversen OE, Kjaer SK, Munoz N, Olsson SE, Paavonen J, Sigurdsson K, Bryan J, Esser MT, Giacoletti K, James M, Taddeo F, Vuocolo S, Barr E, 2009. The impact of a quadrivalent human papillomavirus (types 6, 11 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol 23:1147-1155.
11. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR. 2009. Efficacy of human papillomavirus vaccines: A systematic quantitative review. Int J Gynecol Cancer 19:1166-1176.
12. Munoz N, Manalastas R, Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A, 2009. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 373:1949-1957.
13. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM, 2009. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 5. [Epub ahead of print].
14. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group, Greenacre M, 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
15. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A, GlaxoSmithKline Vaccine HPV-007 Study Group. 2009. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374: 1975-1985.
16. Szarewski A. 2010. HPV vaccine: Cervarix. Expert Opin Biol Ther 10: 477-487.